Last updated: April 26, 2026
Who supplies aminophylline to pharma and distributors?
Aminophylline is supplied through three main channels: (1) licensed manufacturers producing aminophylline active pharmaceutical ingredient (API), (2) contract manufacturers (CMOs) that package and label finished dosage forms, and (3) chemical distributors that source API and intermediates for onward sale. The specific supplier set varies by region, grade (API vs. excipient grade), and regulatory status (DMF/CEP status for API, NDA/ANDA linkage for finished products).
What supplier profiles exist for aminophylline across the value chain?
1) API manufacturers (aminophylline, anhydrous or hydrate)
- Typically provide aminophylline API in bulk with documentation aligned to DMF or CEP expectations.
- Commonly offer multiple grades tied to pharmacopoeial compliance (USP/BP/EP) and impurity specifications.
2) Finished dosage form manufacturers (injectables, tablets)
- Produce and package aminophylline as an injectable or oral solid product.
- Source API from one or more approved upstream suppliers, then control the finished product via GMP manufacturing.
3) Chemical distributors (repackaging and B2B supply)
- Provide smaller minimum order quantities (MOQ) and shorter lead times.
- Often do not manufacture but distribute sourced material with certificates of analysis (CoA).
Which supplier types matter most for R&D and clinical supply?
- R&D/clinical (API or GMP drug substance): prioritize DMF/CEP-backed API sources with established impurity profiles, traceability, and batch consistency.
- Commercial injectables/tablets (finished product): prioritize finished-goods manufacturers with validated filling, labeling, and stability programs.
- Non-GxP or internal lab use: chemical distributors can be adequate if the end-use does not require clinical/regulatory-grade documentation.
What documentation and compliance signals should you expect from legitimate suppliers?
Suppliers of regulated aminophylline typically provide one or more of the following:
- API regulatory packet: DMF reference (FDA) or CEP (Europe) where applicable, plus CoA with batch-specific assay and impurity limits.
- GxP alignment: GMP manufacturing site registration and quality agreements for clinical/commercial supply.
- Pharmacopoeial compliance: USP/BP/EP conformity statements and analytical methods.
- Change control: notification process for manufacturing site changes, solvent/route changes, or specification revisions.
How to evaluate aminophylline supplier readiness (practical checklist)
API supply readiness
- Pharmacopoeial grade statement (USP/BP/EP as requested).
- CoA format includes: assay, water content (if applicable), and key impurities.
- Batch traceability and documentation tied to manufacturing date and lot.
- Ability to support method transfer or provide analytical method packages when needed.
Finished dosage readiness
- GMP certificate of analysis package for final drug product.
- Stability data (real-time and accelerated) for the intended strength and container-closure system.
- Packaging format: vial type, stoppers, labeled volume/strength, and carton configuration.
- Serialization and GDP chain-of-custody where required.
Regional supplier landscape: what to expect
Aminophylline supply is usually concentrated among established generics and API players, with supplier density highest where:
- Injectable manufacturing capacity is scaled,
- API production and crystallization facilities exist,
- Regulatory filings (DMFs/CEPs) are maintained.
In practice, procurement teams often narrow supplier lists to those that can deliver:
- Consistent impurity profile across consecutive lots,
- Short lead times for API and finished goods,
- Regulatory documentation aligned to their intended use (clinical vs commercial).
Where to source aminophylline today (actionable procurement routes)
Route A: API through DMF-backed manufacturers
- Best fit for clinical and commercial supply if you need regulatory-grade consistency.
Route B: Finished dosage form via GMP contract manufacturers
- Best fit if you need a packaged injectable/tablet with established stability and labeling.
Route C: Chemical distributors for non-GxP or preliminary work
- Best fit for lab-scale material or early-stage screening when strict regulatory-grade documentation is not required.
Key Takeaways
- Aminophylline procurement typically splits into API manufacturers, finished dosage manufacturers, and chemical distributors.
- For clinical or commercial programs, prioritize suppliers that can provide DMF/CEP-linked documentation, pharmacopoeial compliance, and batch traceability.
- For finished product, supplier selection hinges on GMP readiness, stability/packaging controls, and ability to meet labeling and distribution requirements.
- The supplier list for aminophylline is highly dependent on grade, region, and intended regulatory use (GxP vs non-GxP).
FAQs
-
Is aminophylline typically supplied as API or finished dosage form?
It is supplied as both; API supports manufacturing and finished forms are available as injectable and oral products depending on market.
-
What regulatory documents matter most for aminophylline API?
Look for DMF/CEP linkage where applicable, plus batch CoA, impurity specifications, and site-level GMP documentation.
-
Do finished product manufacturers supply their own aminophylline API?
Usually they source API from qualified upstream suppliers, then control the finished product under GMP.
-
What grades should procurement specify for aminophylline?
Specify pharmacopoeial grade (USP/BP/EP as required) and whether the material is anhydrous or hydrate, based on your formulation and regulatory needs.
-
Where are aminophylline supply constraints most likely to show up?
Constraints tend to appear around lead times for particular grades, specific hydrate/anhydrous forms, and suppliers that can support strict impurity and stability requirements.
References
[1] United States Pharmacopeia (USP). General Notices and Drug Substances/Drug Products monographs relevant to aminophylline specifications. USP.
[2] European Pharmacopoeia (Ph. Eur.). General monographs and aminophylline monograph specifications. European Directorate for the Quality of Medicines (EDQM).
[3] FDA. Drug Master File (DMF) guidance and regulatory framework overview. U.S. Food and Drug Administration.
[4] EDQM/EMA. Certificate of Suitability (CEP) procedures and framework for quality documentation. European Directorate for the Quality of Medicines (EDQM).
